nisomycin治疗实验性自身免疫性脑脊髓炎

Objective：Anisomycin was used to treat Experimental Allergic Encephalomylitis in vivo to observe in vivo effect. Methods: Each female C57BL/6 mouse was immunized subcutaneously with 200 μg of MOG35-55. All mice were randomly distributed into three groups: normal control, EAE and anisomycin groups. The mice were intraperitoneally treated with anisomycin for one week. And the control group and the EAE group were injected intraperitoneally with an equal volume of PBS. The mouse brains were taken out at eighteen days after the immune to observe histopathological changes by HE staining. Results: Latency of the mice in the EAE or anisomycin group was 12 to 13 days. The mice had weight loss, hind limb weakness and hindquarter completely unable to performance. Clinical signs of the mice treated by anisomycin were significantly slighter than those of EAE mice. Brain tissues of EAE mice had EAE typical pathological changes, such as perivascular inflammatory cell infiltration in the "sleeve-like". Anisomycin treatment resulted in the reduction of inflammatory cell infiltration into the brain tissues, compared with the EAE group. Conclusion: Anisomycin has therapeutic effect on the EAE mice to some extent.